


REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/US2004/002425 into the U.S. National Phase of prosecution.

In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Entry of this amendment into the record is requested.

Respectfully submitted,



Laura K. Madden

Agent for Applicants


Registration No. 48,352

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7339
Facsimile (610) 270-5090

N:\lkm\PU Cases\PU60030\preliminary amendment.doc

Abstract

Compounds of the formula (I) are disclosed which are NK2 and NK3 receptor antagonists and are useful in the treatment of respiratory diseases:



or a pharmaceutically acceptable salt thereof.